Preimushchestva fiksirovannoy kombinatsii saksagliptina i metformina modifitsirovannogo vysvobozhdeniya (Kombogliz Prolong) v terapii SD 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease that requires long-term continuous administration of glucose-lowering drugs and the need to intensify therapy. According to current Russian recommendations, administration of combination of two or even three oral hypoglycemic agents with complementary mechanisms of action is clinically justified. The use of fixed combinations in the treatment of T2DM can be related to the advantages of therapy such as convenient regimen of administration of the drug and high treatment compliance, resulting in improvement of metabolic and clinical outcomes of T2DM. Fixed combination of saxagliptin and metformin extended-release - Komboglyze Prolong® - opens up new prospects for the therapy of diabetic patients, offering effective and more convenient treatment regimen for the doctor and the patient. The advantages of this combination include not only a once daily administration of drug and improvement of all parameters of glycemic control, but also proven safety components, including a low risk of hypoglycemia, no negative impact on the weight and increase of risk of pancreatitis and cardiovascular diseases.

Full Text

Restricted Access

About the authors

A. S Ametov

Email: endocrin@mtu-net.ru

References

  1. Guillausseau P.J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab. 2003;29:79-81.
  2. Rozenfeld Y, Hunt J.S., Plauschinat C., Wong K.S. Oral antidiabetic medication adherence and gly-cemic control in managed care. Am. J. Manag Care. 2008;14:71-5.
  3. Pladevall M, Williams L.K., Potts L.A., Divine G., Xi H, Lafata J.E. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004; 27:2800-805.
  4. Schectman J.M., Nadkarni M.M., Voss J.D. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25:1015-21.
  5. Ho P.M., Rumsfeld J.S., Masoudi F.A., McClure D.L., Plomondon M.E., Steiner J.F., Magid D.J. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern. Med. 2006;166:1836-41.
  6. Leichter S.B. Making outpatient care of diabetes more efficient: analyzing noncompliance. Clin. Diabetes. 2005;23:187-90.
  7. Odegard P.S., Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33:1014-29.
  8. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-24.
  9. Paes A.H., Bakker A., Soe-Agnie C.J. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-17.
  10. Han S., Iglay K, Davies M.J., Zhang Q., Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr. Med. Res. Opin. 2012;8(6):969-77.
  11. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet. Med. 2010;27(7):739-43.
  12. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5, 5,0 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от 30.03.2012.
  13. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I.; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N. Engl. J. Med. 2013.
  14. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. 6-й вып. М., 2013. 118 с.
  15. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of clinical endocrinologists / American college of endocrinology consensus panel on Type 2 diabetes mel-litus: an algorithm for glycemic control. Endocr. Pract. 2009;15:540-59.
  16. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
  17. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med 1995;333:550-54.
  18. Hundal R.S., Inzucchi S.E. Metformin: newunder-standings, new uses. Drugs. 2003;63:1879-94.
  19. Setter S.M., Iltz J.L., Thams J., Campbell R K. Metformin hydrochloride in the treatment of Type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin. Ther. 2003;25:2991-3026.
  20. Consoli A., Gomis R., Halimi S., et al. Initiating oral glucose-lowering therapy with metformin in Type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab. 2004;30:509-16.
  21. Anfossi G., Russo I., Bonomo K., Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of Type 2 diabetes mellitus. Curr. Vasс. Pharmacol. 2010;8:327-37.
  22. Messaoudi S.E., Rongen G.A., de Boer R.A., Riksen N.P. The cardioprotective effects of metformin. Curr. Opin. Lipidol 2011;22:445-53.
  23. Инструкция по медицинскому применению лекарственного препарата Глюкофаж® Лонг (таблетки, пролонгированного действия, 500 мг). Регистрационное удостоверение ЛСР 002098/10 (изменение №1) от 08.02.2013
  24. Gusler G., Gorsline J., Levy G., Zhang S.Z., Weston I.E., Naret D., Berner B. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol. 2001; 41:655-61.
  25. Schwartz S., Fonseca V., Berner B., Cramer M., Chiang Y.K., Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759-64.
  26. Fujioka K., Pans M., Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther. 2003;25(2):515-29.
  27. Scheen А. Saxagliptin plus metformin combination therapy. Expert. Rev. Endocrinol. Metab. 2012;7(2):151-64.
  28. Mulherin A.J., Oh A.H., Kim H, Grieco A., Lauf-fer L.M, Brubaker P.L. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152(12):4610-19.
  29. Инструкция по медицинскому применению лекарственного препарата Комбоглиз Пролонг® (таблетки с модифицированным высвобождением, покрытые оболочкой). Регистрационное удостоверение ЛП-002068 от 14.05.2013.
  30. Boulton D.W., Smith C.H., Li L., Huang J., Tang A., LaCreta F.P. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin. Drug Investig. 2011;31(9):619-30.
  31. Fonseca V, Zhu T., Karyekar C., Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes, Obesity, Metabolism. 2012;14:365-71.
  32. Rosenstock J., Gross J.L., Aguilar-Salinas C., Hissa M., Berglind N., Ravichandran S., Fleming D. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabet Med. 2013
  33. Jadzinsky M., Pfutzner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab. 2009;11: 611-22.
  34. Pfutzner A., Paz-Pacheco E., Allen E, Frederich R., Chen R. Initial combination therapy with saxa-gliptin and metformin provides sustained gly-caemic control and is well tolerated for up to 76 weeks. Diabetes Obes. Metab. 2011; 13:567-76.
  35. Goke B., Gallwitz B., Eriksson J., Hellqvist A., Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619-31.
  36. Goke B., Gallwitz B., Eriksson J.G., Hellqvist A., Gause-Nilsson I. Saxagliptin vs. glipizide as addon therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int. J. Clin. Pract. 2013;67(4):307-16.
  37. Rao A., Kuhadiya N., Reynolds K., Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care. 2008;31:1672-78.
  38. Olsson J., Lindberg G., Gottsater M., Lindwall K., Sjostrand A., Tisell A., Melander A. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000;43:558-60.
  39. Monami M., Luzzi C, Lamanna C, Chiasserini V., Addante F., Desideri C.M., Masotti G., Marchionni N., Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab. Res. Rev. 2006; 22:477-82.
  40. Phung O.J.,Schwartzman E.,Allen R.W.,Engel S.S., Rajpathak S.N. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013 May 11. doi: 10.1111/dme.12232.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies